The diagnostic efficacy of exome data analysis using fixed neurodevelopmental gene lists: Implications for prenatal setting

Prenat Diagn. 2021 May;41(6):701-707. doi: 10.1002/pd.5929. Epub 2021 Mar 31.

Abstract

Objective: Laboratories performing prenatal exome sequencing (ES) frequently limit analysis to predetermined gene lists. We used a diagnostic postnatal ES cohort to assess how many of the genes diagnosed are not included in a number of select fixed lists used for prenatal diagnosis.

Methods: Of 601 postnatal ES tests, pathogenic variants related to neurodevelopmental disorders were detected in 138 probands. We evaluated if causative genes were present in the following: (1) Developmental Disorders Genotype-Phenotype database list, (2) a commercial laboratory list for prenatal ES, (3) the PanelApp fetal anomalies panel, and (4) a published list used for prenatal diagnosis by ES (Prenatal Assessment of Genomes and Exomes study).

Results: The percentages of cases where the diagnosed gene was not included in the selected four lists were; 11.6%, 17.24%, 23.2%, and 10.9%, respectively. In 13/138 (9.4%) cases, the causative gene was not included in any of the lists; in 4/13 (∼30%) cases noninclusion was explained by a relatively recent discovery of gene-phenotype association.

Conclusions: A significant number of genes related to neurocognitive phenotypes are not included in some of the lists used for prenatal ES data interpretation. These are not only genes related to recently discovered disorders, but also genes with well-established gene-phenotype.

MeSH terms

  • Exome Sequencing / methods
  • Exome Sequencing / standards*
  • Exome Sequencing / statistics & numerical data
  • Female
  • Fetus
  • Humans
  • Noninvasive Prenatal Testing / methods
  • Noninvasive Prenatal Testing / standards*
  • Noninvasive Prenatal Testing / statistics & numerical data
  • Pregnancy